CXCL9 and neoplasm: Recently, it was shown that neutralizing TIM-3, which is expressed on many cell types under homeostatic conditions but is restricted to CD103+ cDC1 inside the tumor, promotes CXCL9 expression by these cells and indirectly enhances the CD8+ T cell response in a breast cancer model (31).